Sector News

Longtime GlaxoSmithKline CFO Dingemans heads for the exit

May 9, 2018
Life sciences

GlaxoSmithKline CEO Emma Walmsley has hired more than a few new executives since taking the baton from Andrew Witty. And now, she’ll have the opportunity to fill another big slot.

Wednesday, GSK said CFO Simon Dingemans would retire from the British drugmaker and step down from its board next May. The company is now kicking off a “thorough, global search”—both internal and external—to find his replacement.

Dingemans, who joined Glaxo from Goldman Sachs, has been with the company since 2011, overseeing the Big Pharma’s multibillion-dollar asset swap with Novartis in 2015. He’s also been helping Walmsley craft the company’s new strategy since she took the helm last March.

“Since joining GSK, Simon has played a very significant role in shaping the company. He has taken a consistent and sustained approach to support investment and improve operational efficiencies in all three of our global businesses,” Walmsley said in a statement, highlighting his “support and partnership” and “his counsel to me.”

Walmsley, who took over from Andrew Witty when he retired last year, replaced 40% of GSK’s top management team within her first 9 months in the top spot. So far, her most high-profile hires have included Roche veteran Hal Barron for R&D chief and former AstraZeneca executive Luke Miels for pharma head.

A slew of executive exits at Glaxo has made room for those hires, with several company leaders following Witty out the door. Last November, R&D chief Patrick Vallance took a job with the U.K. government. Earlier that year, top pharma dog Abbas Hussain’s departure made way for Miels. And before that, vaccines chairman Moncef Slaoui and ViiV head Dominique Limet both decided to say their goodbyes.

With respiratory blockbuster Advair heading toward generic competition and pressure from payers and rivals weighing on other key products, the CFO switch could come at a busy time for Glaxo. The way Dingemans sees it, though, it’s the “right time for me to take this decision.”

“With the new strategy set, we have established strong foundations to deliver improved business and financial performance,” he said in a statement.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.